Article ; Online: Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
2021 Volume 62, Issue 12, Page(s) 2928–2938
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to ... ...
| Abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; COVID-19 ; Humans ; Leukemia, Myeloid, Acute/epidemiology ; Leukemia, Myeloid, Acute/therapy ; Lopinavir ; Risk Factors ; SARS-CoV-2 | |||||
| Chemical Substances | Lopinavir (2494G1JF75) | |||||
| Language | English | |||||
| Publishing date | 2021-07-22 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article ; Multicenter Study ; Observational Study | |||||
| ZDB-ID | 1042374-6 | |||||
| ISSN | 1029-2403 ; 1042-8194 | |||||
| ISSN (online) | 1029-2403 | |||||
| ISSN | 1042-8194 | |||||
| DOI | 10.1080/10428194.2021.1948031 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2997: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.